Singapore, Oct. 6 -- Germfree, a full-lifecycle engineering and manufacturing partner for mission-critical environments across life sciences, healthcare and biocontainment, has launched a new aseptic biopharmaceutical isolator designed to provide a flexible, modular Grade A processing environment for cell and gene therapy applications.

The new technology, made and serviced in the U.S., will enable CGT developers to bolster their contamination control strategy around open steps in manufacturing workflows.

Germfree is bringing the new aseptic isolator to market in response to rising customer demand, especially for their critical role in the manufacture of CGTs.

The introduction of the new platform aligns with Germfree's mission to create...